HOME › Research Insight › New product launches was the major growth strategy adopted by players in the Molecular Biology Enzymes and Kits & Reagents Market
New product launches was the major growth strategy adopted by players in the Molecular Biology Enzymes and Kits & Reagents Market
The overall molecular biology enzymes and kits & reagents market is dominated by Thermo Fisher Scientific, Inc. (U.S.) and Merck KGaA (Germany). These players jointly accounted for approximately 64% of the market in 2016. Other players having significant presence in this market include New England Biolabs, Inc. (U.S.), Promega (U.S.), Illumina, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), F. Hoffmann-la Roche Ltd. (Switzerland), Takara Bio Inc. (Japan), QIAGEN N.V. (The Netherlands), and Becton, Dickinson and Company (U.S.).
Thermo Fisher Scientific, Inc. (U.S.) is among the leading players in the molecular biology enzymes and kits & reagents market. A wide product portfolio, high focus on increasing company presence in the emerging economies, and continuous launch of new and innovative products are contributing to the company’s dominance in this market. The company’s products are made available through its broad sales force and a global network of resellers and distributors. The company has approximately 12,000 sales and service personnel, including highly trained technical specialists. The company has high focus on innovation through the launch of new products and acquisitions. During 2013 to 2016, the company made several acquisitions. For instance, in March 2016, Thermo Fisher acquired Affymetrix, Inc. (U.S.), a provider of innovative technologies that enable multiplex and parallel analysis of biological systems at the cell, protein, and gene levels. The acquisition was aimed at integrating Affymetrix’s major product groups into Thermo Fisher Scientific’s existing businesses. Merck KGaA (Germany) is another major player in the molecular biology enzymes and kits & reagents market. The company has a well-established brand and has 72 production locations across 66 countries. To maintain its position in the market, the company is strategically focusing on collaborating with other players and end users, including Amoy Diagnostics Co., Ltd. (AmoyDx) (China) (2016), the European Molecular Biology Laboratory (EMBL) (Germany) (2016), and Biocartis NV (Belgium) (2016). The company has also focused on expansion to meet market demands and enhance its capabilities. For example, Merck expanded its viral and gene production facility in California, U.S. in May 2016 to incorporate single -use equipment for commercial bulk drug and clinical production.
The other players in this market have implemented various strategies to expand their global footprints and increase their market shares. Major growth strategies followed by market players include new product launches, distribution agreements, collaborations, expansions, acquisitions, alliances, approvals, and partnerships. New product launches accounted for a major share followed by alliances/agreements/partnerships/collaborations, which accounted for the second-largest share of the total number of key growth strategies adopted by players in the molecular biology enzymes and kits & reagents market during 2013 to 2016. Approvals, CE markings, new service launches, new technology launches, market developments and grants are some of the other strategies adopted by players to achieve growth in the molecular biology enzymes and kits & reagents market.
Molecular Biology Enzymes and Kits & Reagents Market by Product (Kits & Reagents, Enzymes), Application (PCR, Sequencing, Cloning), End User (Academic & Research Institutes, Hospitals & Diagnostic Centers) - Trends & Global Forecasts to 2021
Markets and Markets
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune, Maharashtra 411013, India